Evotec International

Christine Guenther, M.D., Ph.D., Executive Vice President, Head of Global Cell Therapy Translation, Managing Director Evotec Modena

Hamburg, Germany

(NASDAQ : EVT)

Evotec is a biotechnology company focused on delivering highly effective new therapeutics to patients. The company leverages its multimodality platforms for proprietary projects and pipeline co-creation with partners including pharma, biotech, academics, and other healthcare stakeholders. Our business model is flexible, ranging from service-based support to strategic partnerships.  Within cell therapy, Evotec offers a fully integrated end-to-end platform to move iPSC-based from inception to the clinic, including in-house GMP manufacturing capabilities with clinical supply. Our proprietary iPSC-based cell therapy pipeline is one of the broadest in the industry and includes anti-tumor therapies (NK cells, macrophages, αβ T cells, γδ T cells), regenerative therapies (beta cells, cardiomyocytes, photoreceptors) and immune-modulation therapies.   In addition, Evotec provides integrated drug development solutions, covering safety assessment, CMC, process and analytical development, regulatory and clinical services for autologous and allogeneic cell therapy candidates.

www.evotec.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions